Qiagen faces fraud investigation over conflicting 2026 growth forecasts for QuantiFERON sales

The Schall Law Firm is investigating Qiagen N.V. for potential securities law violations after the company gave conflicting guidance on its QuantiFERON product's growth. In February 2026, Qiagen forecasted 6-7% growth for QuantiFERON, but by April, the CFO revised this, projecting sales to remain flat through 2026 and only normalize growth in 2027. This discrepancy has prompted a shareholder fraud investigation, and affected investors are encouraged to contact the law firm for potential legal action. The case highlights risks of misleading corporate forecasts impacting investor decisions.